HOOKIPA Pharma Provides Update on Business Priorities and

HOOKIPA to prioritize clinical development of HB-200 for the treatment of HPV16+ head and neck cancers and Gilead-partnered programs in infectious...

Related Keywords

Austria ,Vienna ,Wien ,Michael Kaiser ,Joern Aldag ,Nasdaq ,Pharma Inc ,Exchange Commission ,Investigational New Drug ,Chief Executive Officer ,Disease Programs ,Human Papillomavirus ,Private Securities Litigation Reform Act ,Roche Collaboration Agreement ,Nasdaq Hook ,Hookipa Pharma Inc ,Hookipa ,Hookipa Pharma ,Sb 200 ,Head And Neck Cancer ,